Affiliation: Texas Medical Center
- Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study GroupJ Grotta
Department of Neurology, University of Texas Health Science Center at Houston 77030, USA
Stroke 28:2338-46. 1997..The present multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of lubeluzole in the treatment of ischemic stroke...
- tPA-associated reperfusion after acute stroke demonstrated by SPECTJ C Grotta
Department of Neurology, University of Texas Health Science Center, Houston 77030, USA
Stroke 29:429-32. 1998....
- Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapyJ C Grotta
Department of Neurology, University of Texas Houston Medical School, Houston, Texas, USA
Stroke 30:1528-33. 1999..We performed a detailed review of selected baseline CT scans from the NINDS rt-PA Stroke Trial to test agreement among experienced stroke specialists and other physicians on the presence of early CT ischemic changes...
- Neuroprotective therapyJ C Grotta
Rev Neurol (Paris) 155:644-6. 1999..Progress depends on designing our clinical trials to better simulate the experimental conditions under which these drugs have been found to be effective...
- Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzoleJ Grotta
University of Texas Houston Medical School, Houston, TX 77030, USA
Cerebrovasc Dis 12:258-63. 2001..A neuroprotective drug may be safe and effective if given very early and in combination with recombinant tissue-type plasminogen activator (rt-PA) to acute stroke patients. No clinical trial has yet tested this hypothesis...
- Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trialE Clarke Haley
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
Stroke 41:707-11. 2010..If promise was established, then the trial would continue as a Phase III efficacy trial comparing the selected tenecteplase dose to standard rtPA...
- Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhageStephan A Mayer
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA
N Engl J Med 358:2127-37. 2008..We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes...
- Intraventricular hemorrhage: Anatomic relationships and clinical implicationsH Hallevi
Department of Neurology, 6431 Fannin Street, MSB 7 044, Houston, TX 77030, USA
Neurology 70:848-52. 2008..The purpose of this study was to examine the relationship between ICH volume and anatomic location to IVH, and to determine if ICH decompression into the ventricle is truly beneficial...
- Hypothermia after cardiac arrest: feasibility and safety of an external cooling protocolR A Felberg
Department of Neurology, Stroke Treatment Team, University of Texas-Houston Medical School, Houston, Texas, USA
Circulation 104:1799-804. 2001..CONCLUSIONS: Mild-to-moderate induced hypothermia after cardiac arrest is feasible and safe. However, external cooling is slow and imprecise. Efforts to speed the start of cooling and to improve the cooling process are needed...
- Acute stroke care in non-urban emergency departmentsW S Burgin
Stroke Program, Department of Neurology, University of Texas Medical School-Houston, TX 77030, USA
Neurology 57:2006-12. 2001..The use of heparin is common, more so than aspirin treatment. These facts argue for educational interventions aimed at non-urban physicians to improve evidence-based medical practice...
- Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIaR M Sugg
Department of Neurology, The University of Houston Medical School, Houston, TX 77030, USA
Neurology 67:1053-5. 2006..Elevated troponin occurred in 20% treated vs 3% nontreated (p = 0.02). Myocardial infarction occurred in 10% vs 1% (p = 0.01). We found a significant increase in myocardial injury in rFVIIa treated patients...